Alnylam Pharmaceuticals ALNY
NASDAQ ALNY
$159.85 +8.21 (+5.41%)
At close: Nov 11, 2026 · 4:00 PM EST

Alnylam Pharmaceuticals (ALNY) Short term Debt (2009 - 2026)

Updated

Analysis

Alnylam Pharmaceuticals (ALNY) Short term Debt (2009 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Alnylam Pharmaceuticals 20.30 Bn 7.49 Bn 1.10 Bn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 361.53 Mn
Dec 31, 2010 412,000.00
Dec 31, 2009 317,000.00
API Access

Alnylam Pharmaceuticals Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=ALNY&period=max&api_key=YOUR_API_KEY